ATE376062T1 - Enhancer des menschlichen glandulären kallikreingens, vektoren die ihn enthalten und methoden für seine verwendung - Google Patents
Enhancer des menschlichen glandulären kallikreingens, vektoren die ihn enthalten und methoden für seine verwendungInfo
- Publication number
- ATE376062T1 ATE376062T1 AT98938394T AT98938394T ATE376062T1 AT E376062 T1 ATE376062 T1 AT E376062T1 AT 98938394 T AT98938394 T AT 98938394T AT 98938394 T AT98938394 T AT 98938394T AT E376062 T1 ATE376062 T1 AT E376062T1
- Authority
- AT
- Austria
- Prior art keywords
- methods
- enhancers
- kallic
- enhancer
- cleaning
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Percussion Or Vibration Massage (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5452397P | 1997-08-04 | 1997-08-04 | |
US7654598P | 1998-03-02 | 1998-03-02 | |
US12783498A | 1998-08-03 | 1998-08-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE376062T1 true ATE376062T1 (de) | 2007-11-15 |
Family
ID=27368663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT98938394T ATE376062T1 (de) | 1997-08-04 | 1998-08-04 | Enhancer des menschlichen glandulären kallikreingens, vektoren die ihn enthalten und methoden für seine verwendung |
Country Status (6)
Country | Link |
---|---|
US (1) | US6916918B2 (de) |
EP (1) | EP1002103B1 (de) |
AT (1) | ATE376062T1 (de) |
AU (1) | AU8692598A (de) |
DE (1) | DE69838584T2 (de) |
WO (1) | WO1999006576A1 (de) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5998205A (en) * | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
EP1905837A1 (de) * | 1997-03-03 | 2008-04-02 | Cell Genesys, Inc. | Adenovirusvektoren mit heterologen Transkriptionsregulationselementen und diese verwendende Verfahren |
AU3292499A (en) * | 1998-02-12 | 1999-08-30 | Calydon, Inc. | Prostate cancer drug screening |
US6900049B2 (en) | 1998-09-10 | 2005-05-31 | Cell Genesys, Inc. | Adenovirus vectors containing cell status-specific response elements and methods of use thereof |
US6495130B1 (en) | 1998-12-30 | 2002-12-17 | Calydon, Inc. | Target cell-specific adenoviral vectors containing E3 and methods of use thereof |
DE19928342A1 (de) * | 1999-06-21 | 2000-12-28 | Deutsches Krebsforsch | Vektoren zur gentherapeutischen Tumorbehandlung |
CN1314364A (zh) * | 2000-03-17 | 2001-09-26 | 上海博德基因开发有限公司 | 一种新的多肽——前列腺特异性膜抗原18和编码这种多肽的多核苷酸 |
US7048920B2 (en) | 2000-03-24 | 2006-05-23 | Cell Genesys, Inc. | Recombinant oncolytic adenovirus for human melanoma |
US6911200B2 (en) | 2000-03-24 | 2005-06-28 | Cell Genesys, Inc. | Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation |
AU2001245944B2 (en) | 2000-03-24 | 2007-01-18 | Cell Genesys, Inc. | Human urothelial cell specific uroplakin transcriptional regulatory sequences, vectors comprising the same, and methods of use thereof |
AU2001247648B2 (en) * | 2000-03-24 | 2006-03-30 | Cold Genesys, Inc. | Cell-specific adenovirus vectors comprising an internal ribosome entry site |
US6692736B2 (en) | 2000-03-24 | 2004-02-17 | Cell Genesys, Inc. | Cell-specific adenovirus vectors comprising an internal ribosome entry site |
US6673614B2 (en) | 2000-06-27 | 2004-01-06 | Cell Genesys, Inc. | Rapid methods and kits for detection and semi-quantitation of anti-adenovirus antibody |
EP1207205A1 (de) * | 2000-11-20 | 2002-05-22 | Crucell Holland B.V. | Adenovirale Replikone |
EP1346058B1 (de) * | 2000-12-28 | 2007-05-02 | Per Sonne Holm | Adenovirale systeme und deren anwendungen |
WO2002068627A2 (en) | 2001-02-23 | 2002-09-06 | Novartis Ag | Vector constucts |
US20030235874A1 (en) * | 2002-05-08 | 2003-12-25 | Chinghai Kao | Prostate-specific chimeric enhancers and methods of use thereof |
JP5213298B2 (ja) | 2002-05-27 | 2013-06-19 | ホルム,ペル・ゾンネ | アデノウイルスおよびそれをコードしている核酸の新たな使用 |
US7709224B2 (en) * | 2003-06-03 | 2010-05-04 | Biosante Pharmaceuticals, Inc. | Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site |
US20050136035A1 (en) * | 2003-06-03 | 2005-06-23 | Derek Ko | Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site |
US20050186178A1 (en) * | 2003-08-28 | 2005-08-25 | Ennist David L. | Oncolytic adenoviral vectors encoding GM-CSF |
US7482156B2 (en) | 2003-10-15 | 2009-01-27 | Cell Genesys, Inc. | Hepatocellular carcinoma specific promoter and uses thereof |
WO2005051430A1 (de) | 2003-11-14 | 2005-06-09 | Per Sonne Holm | Neue verwendung von adenoviren und dafür codierenden nukleinsäuren |
US7473418B2 (en) | 2004-03-25 | 2009-01-06 | Cell Genesys, Inc. | Pan cancer oncolytic vectors and methods of use thereof |
JP2006248978A (ja) | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
EP2046308A2 (de) * | 2006-07-25 | 2009-04-15 | The University Court of the University of Dundee | Retinoide und kleine moleküle als nrf2-antagonisten zur verwendung bei der behandlung von erkrankungen im zusammenhang mit abnormaler zellproliferation |
US11298113B2 (en) | 2008-10-01 | 2022-04-12 | Covidien Lp | Device for needle biopsy with integrated needle protection |
US9782565B2 (en) | 2008-10-01 | 2017-10-10 | Covidien Lp | Endoscopic ultrasound-guided biliary access system |
US9186128B2 (en) | 2008-10-01 | 2015-11-17 | Covidien Lp | Needle biopsy device |
US9332973B2 (en) | 2008-10-01 | 2016-05-10 | Covidien Lp | Needle biopsy device with exchangeable needle and integrated needle protection |
US8968210B2 (en) | 2008-10-01 | 2015-03-03 | Covidien LLP | Device for needle biopsy with integrated needle protection |
WO2012003287A2 (en) * | 2010-06-30 | 2012-01-05 | The Johns Hopkins University | Compositions and methods for detecting and quantifying circulating tumor cells ctcs |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
WO2018087720A1 (en) | 2016-11-14 | 2018-05-17 | Novartis Ag | Compositions, methods, and therapeutic uses related to fusogenic protein minion |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4391909A (en) | 1979-03-28 | 1983-07-05 | Damon Corporation | Microcapsules containing viable tissue cells |
US4353888A (en) | 1980-12-23 | 1982-10-12 | Sefton Michael V | Encapsulation of live animal cells |
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US5288641A (en) | 1984-06-04 | 1994-02-22 | Arch Development Corporation | Herpes Simplex virus as a vector |
US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
US5166320A (en) | 1987-04-22 | 1992-11-24 | University Of Connecticut | Carrier system and method for the introduction of genes into mammalian cells |
US4883666A (en) | 1987-04-29 | 1989-11-28 | Massachusetts Institute Of Technology | Controlled drug delivery system for treatment of neural disorders |
WO1989001973A2 (en) | 1987-09-02 | 1989-03-09 | Applied Biotechnology, Inc. | Recombinant pox virus for immunization against tumor-associated antigens |
US5106627A (en) | 1987-11-17 | 1992-04-21 | Brown University Research Foundation | Neurological therapy devices |
US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
EP0454781B1 (de) | 1989-01-23 | 1998-12-16 | Chiron Corporation | Rekombinante zellen für therapien von infektionen und hyperprolieferative störungen und deren herstellung |
US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
WO1991002805A2 (en) | 1989-08-18 | 1991-03-07 | Viagene, Inc. | Recombinant retroviruses delivering vector constructs to target cells |
US5166057A (en) | 1989-08-28 | 1992-11-24 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant negative strand rna virus expression-systems |
GB8919607D0 (en) | 1989-08-30 | 1989-10-11 | Wellcome Found | Novel entities for cancer therapy |
AU7007491A (en) | 1990-02-02 | 1991-08-08 | Schweiz. Serum- & Impfinstitut Bern | Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses |
EP0537299A1 (de) | 1990-03-29 | 1993-04-21 | Gilead Sciences, Inc. | Disulfidkonjugate von oligonukleotid-transportagenten |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
AU7979491A (en) | 1990-05-03 | 1991-11-27 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
CA2082507A1 (en) | 1990-05-11 | 1991-11-12 | George Y. Wu | Targeted protection from cytotoxins |
WO1992005266A2 (en) | 1990-09-21 | 1992-04-02 | Viagene, Inc. | Packaging cells |
JPH06503714A (ja) | 1990-09-25 | 1994-04-28 | ユニバーシティ オブ コネチカット | 細胞内に導入されたポリヌクレオチドの長時間発現 |
JPH07500961A (ja) | 1990-10-01 | 1995-02-02 | ユニバーシティ オブ コネチカット | 細胞による選択的内在化を目的としたウイルス及び細胞の標的設定 |
AU662304B2 (en) | 1990-10-22 | 1995-08-31 | Fox Chase Cancer Center | DNA construct for providing RNA therapy |
DE69129897T2 (de) | 1990-10-25 | 1998-12-17 | Clague Pitman Hodgson | Methode des gentransfers mittels retrotransposons |
DE4104186A1 (de) | 1991-02-12 | 1992-08-13 | Genentech Inc | Neue, ueber endozytose in hoehere eukaryotische zellen aufnehmbare, nukleinsaeure enthaltende komplexe |
WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
US5501662A (en) | 1992-05-22 | 1996-03-26 | Genetronics, Inc. | Implantable electroporation method and apparatus for drug and gene delivery |
WO1993025234A1 (en) | 1992-06-08 | 1993-12-23 | The Regents Of The University Of California | Methods and compositions for targeting specific tissue |
WO1993025698A1 (en) | 1992-06-10 | 1993-12-23 | The United States Government As Represented By The | Vector particles resistant to inactivation by human serum |
GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
WO1994020608A1 (en) | 1993-03-12 | 1994-09-15 | Creighton University | Improved vectors for gene therapy |
DE4340173A1 (de) | 1993-11-25 | 1995-06-01 | Hergeth Hubert A | Verfahren zum Erkennen und Ausschleusen von andersfarbigen Fremdteilen in Faserverarbeitungslinien |
US5698443A (en) * | 1995-06-27 | 1997-12-16 | Calydon, Inc. | Tissue specific viral vectors |
US5830686A (en) | 1994-01-13 | 1998-11-03 | Calydon | Tissue-specific enhancer active in prostate |
US6312699B1 (en) | 1994-03-28 | 2001-11-06 | Uab Research Foundation | Ligands added to adenovirus fiber |
WO1995028494A1 (en) | 1994-04-15 | 1995-10-26 | Targeted Genetics Corporation | Gene delivery fusion proteins |
US5656465A (en) | 1994-05-04 | 1997-08-12 | Therion Biologics Corporation | Methods of in vivo gene delivery |
US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
EP0769063A1 (de) | 1994-06-27 | 1997-04-23 | The Johns Hopkins University | Gezielte freigabe genetischen materials |
AU4690596A (en) | 1994-12-30 | 1996-07-24 | Chiron Viagene, Inc. | Nucleic acid condensing agents with reduced immunogenicity |
WO1996026745A1 (en) | 1995-02-28 | 1996-09-06 | Nature Technology Corporation | Biosynthetic virus vectors for gene therapy |
US6565842B1 (en) | 1995-06-07 | 2003-05-20 | American Bioscience, Inc. | Crosslinkable polypeptide compositions |
US5705385A (en) | 1995-06-07 | 1998-01-06 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
US6197293B1 (en) * | 1997-03-03 | 2001-03-06 | Calydon, Inc. | Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof |
US7001764B2 (en) * | 1995-06-27 | 2006-02-21 | Cell Genesys, Inc. | Compositions comprising tissue specific adenoviral vectors |
US6254862B1 (en) * | 1997-03-03 | 2001-07-03 | Calydon, Inc. | Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof |
US6676935B2 (en) * | 1995-06-27 | 2004-01-13 | Cell Genesys, Inc. | Tissue specific adenoviral vectors |
US5965440A (en) | 1995-12-07 | 1999-10-12 | The General Hospital Corporation | Controlled gene product delivery from a regulatable retroviral vector |
DK0914440T3 (da) | 1996-04-19 | 2007-05-21 | Merial Ltd | Nukleinsyrevaccination mod parvovirusinfektioner |
US6184037B1 (en) | 1996-05-17 | 2001-02-06 | Genemedicine, Inc. | Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell |
US5679559A (en) | 1996-07-03 | 1997-10-21 | University Of Utah Research Foundation | Cationic polymer and lipoprotein-containing system for gene delivery |
US5783435A (en) * | 1996-08-06 | 1998-07-21 | Lamparski; Henry G. | Prostate cancer drug screenings |
US6403370B1 (en) | 1997-02-10 | 2002-06-11 | Genstar Therapeutics Corporation | Oncolytic/immunogenic complementary-adenoviral vector system |
EP1007715A2 (de) * | 1997-03-03 | 2000-06-14 | Calydon, Inc. | Adenovirale vektoren, die heterologe regulatorische elemente für die transkription enthalten und methoden für ihre verwendung |
US6495130B1 (en) * | 1998-12-30 | 2002-12-17 | Calydon, Inc. | Target cell-specific adenoviral vectors containing E3 and methods of use thereof |
US6911200B2 (en) * | 2000-03-24 | 2005-06-28 | Cell Genesys, Inc. | Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation |
-
1998
- 1998-08-04 WO PCT/US1998/016312 patent/WO1999006576A1/en active IP Right Grant
- 1998-08-04 AT AT98938394T patent/ATE376062T1/de not_active IP Right Cessation
- 1998-08-04 EP EP98938394A patent/EP1002103B1/de not_active Expired - Lifetime
- 1998-08-04 DE DE69838584T patent/DE69838584T2/de not_active Expired - Fee Related
- 1998-08-04 AU AU86925/98A patent/AU8692598A/en not_active Abandoned
-
2001
- 2001-06-05 US US09/875,228 patent/US6916918B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DE69838584D1 (de) | 2007-11-29 |
EP1002103A1 (de) | 2000-05-24 |
US6916918B2 (en) | 2005-07-12 |
AU8692598A (en) | 1999-02-22 |
WO1999006576A1 (en) | 1999-02-11 |
EP1002103B1 (de) | 2007-10-17 |
US20020136707A1 (en) | 2002-09-26 |
DE69838584T2 (de) | 2008-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE376062T1 (de) | Enhancer des menschlichen glandulären kallikreingens, vektoren die ihn enthalten und methoden für seine verwendung | |
DE60228212D1 (de) | Neue expressionsvektoren | |
ATE243753T1 (de) | Mch4 und mch5, apoptotische proteasen, dafür kodierende nukleinsäure und verfahren zur verwendung | |
CY1106216T1 (el) | 5´ ESTs ΓΙΑ ΜΗ ΙΣΤΟ-ΕΙΔΙΚΕΣ ΕΚΚΡΙΤΙΚΕΣ ΠΡΩΤΕΪΝΕΣ | |
DE69841110D1 (de) | Verlängerte cdns, die für sekretierte proteine kodieren | |
WO2001019859A3 (en) | LEPIDOPTERAN-ACTIVE BACILLUS THURINGIENSIS δ-ENDOTOXIN COMPOSITIONS AND METHODS OF USE | |
ES2118593T3 (es) | Analogos de nucleotidos de pteridina como sondas fluorescentes de adn. | |
ATE423221T1 (de) | Verwendung von mass-matched nukleotide in der analyse von oligonukleotidmischungen sowie in der hoch-multiplexen nukleinsäuresequenzierung | |
DK1005540T3 (da) | IKK-beta-proteiner, nukleinsyrer og fremgangsmåder | |
ATE437962T1 (de) | Verfahren für die behandlung von proliferativen erkrankungen von brustzellen | |
TR200000930T2 (tr) | Büyüme hormonu sekretagogları. | |
DE69634258D1 (de) | Identifizierung und verwendungen von nematizide bacillus thuringiensis gene, toxine und isolate | |
NZ538852A (en) | Selection and isolation of living cells using mRNA-binding probes | |
AU8881201A (en) | Tnf receptor-like molecules and uses thereof | |
AR016680A2 (es) | Novedosas toxinas pesticidas y secuencias de polinucleotidos que codifican estas toxinas | |
ATE384787T1 (de) | Tripeptidyl-aminopeptidase | |
ATE295888T1 (de) | Genfallen-konstrukt zur identifizierung und isolierung von genen | |
DK0960192T3 (da) | Syntetiske polynukleotider | |
DE602004029598D1 (de) | Minimale dna sequenz, die als chromatin-isolator wirkt, und deren verwendung für die protein-expression | |
ATE208821T1 (de) | Klonierung und expression von genen, kodierend für enzyme aus pilzen, die arabinan abbauen | |
DE69840948D1 (de) | Invertierte terminale repeats von aav, die für die transkription aktiviert sind, zur verwendung in rekombinanten aav-vektoren | |
ATE495255T1 (de) | Identifikation des gens das zum schorfigen phenotyp der maus führt, sowie seines menschlichen orthologs | |
ATE252163T1 (de) | Trennung der metalle der platingruppe | |
DE69632963D1 (de) | Mch3, eine apoptosis-protease, kodierende nukleinsäuren und methoden zur verwendung | |
DE69321720T2 (de) | Für den interleukin-9-rezeptor kodierende nukleinsäuresequenzen bzw. dafür komplementäre nuleinsäuresequenzen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |